Filing summary
Entity note: The supplied filing is Leap Therapeutics, Inc. (Nasdaq: LPTX), not Cypherpunk Technologies Inc. This summary reflects the filing provided.
Business context and reporting period
Leap is a clinical-stage biopharmaceutical company developing antibody therapies for cancer. This Form 10-Q covers the quarter ended March 31, 2023; financial amounts below are in U.S. dollars. Its programs include DKN-01, FL-301, and preclinical FL-302 and FL-501. The company had no approved products and reported no product sales revenue.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 or prior date |
|---|---|---|
| Revenue | No product sales | No product sales |
| Research and development expense | $38.9 million | $7.8 million |
| General and administrative expense | $3.8 million | $2.8 million |
| Operating loss | $42.7 million | $10.6 million |
| Net loss | $41.9 million; $0.32 per share | $10.4 million; $0.09 per share |
| Operating cash used | $12.7 million | $11.5 million |
| Cash and cash equivalents | $102.0 million | $65.5 million at Dec. 31, 2022 |
| Total assets | $106.5 million | $70.4 million at Dec. 31, 2022 |
| Total liabilities | $10.5 million | $11.5 million at Dec. 31, 2022 |
There was no material conventional debt reported; liabilities principally included payables, accrued expenses, lease liabilities, and a preferred-stock warrant liability. The company reported $104.7 million of current assets and $10.3 million of current liabilities at quarter-end. Profit margins are not meaningful because the company had no product revenue and incurred operating losses.
Changes versus the prior comparable period
- R&D expense rose $31.2 million, largely due to a $29.6 million nonrecurring charge for acquired in-process R&D from Flame Biosciences. Excluding that charge, the filing attributes increases mainly to manufacturing, personnel, and related costs.
- Net loss increased $31.5 million. G&A expense increased $0.9 million, including higher professional fees and payroll.
- Cash increased by $36.5 million during the quarter, chiefly because the Flame acquisition brought in $50.4 million of cash. Investing cash flow was positive $49.3 million, while operating cash use was $12.7 million.
- Interest income increased to $0.8 million from an immaterial amount, reflecting higher interest rates. Foreign currency results shifted from a $0.2 million gain to a $0.3 million loss.
Outlook, commentary, and material risks
- Management said March 31 cash was expected to fund operating expenses for at least 12 months from issuance of the financial statements. It expects continuing operating losses and expects R&D spending to increase, subject to funding availability; no specific revenue or earnings guidance was provided.
- Flame was acquired in January 2023 for a combination of common shares, Series X non-voting convertible preferred stock, warrants, and acquisition costs. The acquired portfolio added FL-301 and two preclinical programs. The $29.6 million acquired IPR&D charge was expensed because it had no alternative future use.
- Series X preferred stock representing 136.2 million potential common shares was outstanding at quarter-end, subject to stockholder approval and applicable adjustments. If conversion approval was not obtained within six months of issuance, holders could require cash settlement at fair value, which management warned could materially harm liquidity and require further financing or program cuts. The vote was expected at the 2023 annual meeting; approval was not assured.
- BeiGene declined to exercise its option for DKN-01 rights in specified Asian territories; the parties continued a clinical collaboration. Management reported completion of enrollment in Part A of the DeFianCe Phase 2 study and anticipated presenting long-term Part A DisTinGuish data at the June 2023 ASCO meeting.
- Nasdaq had approved transfer of the shares to the Capital Market, effective May 4, 2023, and granted until October 30, 2023 to regain the minimum bid-price requirement. A proposed reverse stock split was among the measures under consideration; continued listing was not assured.
- Other risks include clinical and regulatory uncertainty, need for additional capital or collaboration funding, potential dilution and sales of shares issued to former Flame holders, and possible anti-dilution adjustments to existing warrants. The filing reported no material legal proceedings.
Important facts for investors to verify
- Whether stockholders approved conversion of Series X preferred stock and whether any cash-settlement obligation arose.
- Current cash runway, quarterly operating cash use, and funding needs as clinical spending changes.
- Nasdaq bid-price compliance status and any reverse stock split action.
- Clinical trial progress and data for DKN-01 and FL-301, including any subsequent disclosures after this filing.
- Potential dilution from preferred conversion, warrants, equity awards, and resale of shares issued in the Flame transaction.